Adenovirally delivered tumor necrosis factor-α improves the antiglioma efficacy of concomitant radiation and temozolomide therapy

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6217-6223

  Yamini, Bakhtiar ^a,c   Yu, Xiaohong ^a   Pytel, Peter ^b   Galanopoulos, Nicholas ^a   Rawlani, Vinay ^a   Veerapong, Jula ^a   Bickenbach, Kai ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IONIZING RADIATION; MONOTHERAPY; MOUSE; MYELINATION; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; DNA, COMPLEMENTARY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35948994588     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1421     Document Type: Article

References (42)

1. Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma-multiforme. Int J Radiat Oncol Biol Phys 2001;51:100-7.
2. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
3. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988;48:2179-83.
4. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J 1990;4:3215-23.
5. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039-44.
6. Lejeune F, Lienard D, Eggermont A, et al. Clinical experience with high-dose tumor necrosis factor a in regional therapy of advanced melanoma. Circ Shock 1994;43:191-7.
7. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
8. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995;1:786-91.
9. Park JO, Lopez CA, Gupta VK, et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002;110:403-10.
10. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
11. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
12. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
13. Ghosh S, May MJ, Kopp EB. NF-κ B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
14. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
15. Yamagishi N, Miyakoshi J, Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor κB activation in human malignant glioma cells. Int J Radiat Biol 1997;72:157-62.
16. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
17. Karran P, Macpherson P, Ceccotti S, Dogliotti E, Griffin S, Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem 1993;268:15878-86.
18. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
19. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
20. Yamini B, Yu X, Dolan ME, Wu MH, Kufe DW, Weichselbaum RR. Inhibition of nuclear factor-{κ}B activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res 2007;67:6889-98.
21. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998;5:293-300.
22. Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR. Transcriptional targeting of adenovirally delivered tumor necrosis factor {α} by temozolomide in experimental glioblastoma. Cancer Res 2004;64:6381-4.
23. Kanno T, Brown K, Siebenlist U. Evidence in support of a role for human T-cell leukemia virus type I tax in activating NF-κB via stimulation of signaling pathways. J Biol Chem 1995;270:11745-8.
24. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000;92:326-33.
25. Goldbrunner RH, Wagner S, Roosen K, Tonn JC. Models for assessment of angiogenesis in gliomas. J Neurooncol 2000;50:53-62.
26. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003;10:935-40.
27. Palmer DH, Chen MJ, Searle PF, Kerr DJ, Young LS. Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. Gene Ther 2005;12:1187-97.
28. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-30.
29. Guha A, Mukherjee J. Advances in the biology of astrocytomas. Curr Opin Neurol 2004;17:655-62.
30. Weichselbaum RR, Kufe DW, Hellman S, et al. Radiation-induced tumour necrosis factor-α expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002;3:665-71.
31. Niranjan A, Moriuchi S, Lunsford LD, et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF- α and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000;2:114-20.
32. Ehtesham M, Samoto K, Kabos P, et al. Treatment of intracranial glioma with in situ interferon-γ and tumor necrosis factor-α gene transfer. Cancer Gene Ther 2002;9:925-34.
33. Sampson JH, Ashley DM, Archer GE, et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 1997;41:1365-72; discussion 72-3.
34. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004;64:6858-62.
35. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G. TNF-α transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997;72:137-41.
36. Ashley DM, Sampson JH, Archer GE, Hale LP, Bigner DD. Local production of TGF β1 inhibits cerebral edema, enhances TNF-α induced apoptosis and improves survival in a murine glioma model. J Neuroimmunol 1998;86:46-52.
37. Nakatani K, Yamakuni T, Kondo N, et al. {γ}-Mangostin inhibits inhibitor-{κ}B kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. Mol Pharmacol 2004;66:667-74.
38. Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther 2000;7:13-9.
39. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5:1256-63.
40. Ding GR, Honda N, Nakahara T, et al. Radiosensitization by inhibition of IκB-α phosphorylation in human glioma cells. Radiat Res 2003;160:232-7.
41. Terasima T, Tolmach LJ. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 1963;140:490-2.
42. Liang BC, Thornton AF, Jr., Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991;75:559-63.